Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial (original) (raw)

Abstract

Observational studies suggest that vitamin D may lower the risk of type 2 diabetes. However, data from long-term trials are lacking. The Vitamin D and Type 2 Diabetes (D2d) study is a randomized clinical trial designed to examine whether a causal relationship exists between vitamin D supplementation and the development of diabetes in people at high risk for type 2 diabetes.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (40)

  1. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009;32:2225-2229
  2. Atlanta, GA, Centers for Disease Control and Prevention, 2011
  3. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 di- abetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
  4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Re- search Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM random- ised trial. Lancet 2002;359:2072-2077
  5. Zinman B, Harris SB, Neuman J, et al. Low- dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mel- litus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103-111
  6. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 di- abetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-2029
  7. Song Y, Wang L, Pittas AG, et al. Blood 25- hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective stud- ies. Diabetes Care 2013;36:1422-1428
  8. Afzal S, Bojesen SE, Nordestgaard BG. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Clin Chem 2013;59:381-391
  9. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lan- cet Diabetes Endocrinol 2014;2:76-89
  10. Pittas AG, Harris SS, Stark PC, Dawson- Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007;30:980-986
  11. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementa- tion on pancreatic b cell function, insulin sensi- tivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabe- tes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 2011;94:486-494
  12. Al-Daghri NM, Alkharfy KM, Al-Othman A, et al. Vitamin D supplementation as an adjuvant therapy for patients with T2DM: an 18-month prospective interventional study. Cardiovasc Di- abetol 2012;11:85
  13. Harris SS, Pittas AG, Palermo NJ. A random- ized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in over- weight and obese African Americans. Diabetes Obes Metab 2012;14:789-794
  14. Davidson MB, Duran P, Lee ML, Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care 2013;36:260-266
  15. Institute of Medicine. Dietary Reference In- takes for Calcium and Vitamin D. Washington, DC, The National Academies Press, 2011
  16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an En- docrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930
  17. Engelman CD. Vitamin D recommenda- tions: the saga continues. J Clin Endocrinol Metab 2011;96:3065-3066
  18. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine So- ciety vitamin D guideline. J Clin Endocrinol Metab 2012;97:1146-1152
  19. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vi- tamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012;97:1153-1158
  20. de Boer IH, Levin G, Robinson-Cohen C, et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 2012;156: 627-634
  21. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009;169:626- 632
  22. Pittas AG, Sun Q, Manson JE, Dawson- Hughes B, Hu FB. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabe- tes in women. Diabetes Care 2010;33:2021- 2023
  23. Pittas AG, Chung M, Trikalinos T, et al. Sys- tematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-314
  24. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008;19:666-671 25. von Hurst PR, Stonehouse W, Coad J. Vita- min D supplementation reduces insulin resis- tance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient -a randomised, placebo-controlled trial. Br J Nutr 2010;103:549-555
  25. Pittas AG, Dawson-Hughes B, Li T, et al. Vita- min D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29:650- 656
  26. Gallagher JC, Sai A, Templin T 2nd, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med 2012;156:425-437
  27. Drincic A, Fuller E, Heaney RP, Armas LA. 25- Hydroxyvitamin D response to graded vitamin D 3 supplementation among obese adults. J Clin Endocrinol Metab 2013;98:4845-4851
  28. Cox DR. Regression models and life-tables.
  29. J R Stat Soc Series B 1972;34:187-220
  30. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Bio- metrics 1983;39:499-503
  31. Forouhi NG, Ye Z, Rickard AP, et al. Circu- lating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia 2012;55: 2173-2182
  32. Haybittle JL. Repeated assessment of re- sults in clinical trials of cancer treatment. Br J Radiol 1971;44:793-797
  33. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requir- ing prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34: 585-612
  34. Scragg R. Vitamin D and type 2 diabetes: are we ready for a prevention trial? Diabetes 2008; 57:2565-2566
  35. Grant WB, Cross HS, Garland CF, et al. Esti- mated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol 2009; 99:104-113
  36. Witham MD. Vitamin D deficiency: more evidence is needed before general supplemen- tation. BMJ 2008;336:1451
  37. Mathieu C. Vitamin D and diabetes: the devil is in the D-tails. Diabetologia 2010;53: 1545-1548
  38. Guallar E, Miller ER 3rd, Ordovas JM, Stranges S. Vitamin D supplementation in the age of lost innocence. Ann Intern Med 2010; 152:327-329
  39. Osei K. 25-OH vitamin D: is it the universal panacea for metabolic syndrome and type 2 di- abetes? J Clin Endocrinol Metab 2010;95:4220- 4222
  40. Shapses SA, Manson JE. Vitamin D and pre- vention of cardiovascular disease and diabetes: why the evidence falls short. JAMA 2011;305: 2565-2566